on March 2, 2006
Published online before print March 2, 2006, doi: 10.1161/01.STR.0000208214.46093.d5
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 14, 2005
From the Department of Neurosurgery (C.M.M., F.Y., T.N., P.H.C.), Department of Neurology and Neurological Sciences and Program in Neurosciences, Stanford University School of Medicine, Stanford, Calif; and Maxygen, Inc (S.J.L.), Redwood City, Calif. * To whom correspondence should be addressed. E-mail: phchan{at}stanford.edu.
Background and Purpose--Compelling evidence supporting the role of inflammation in the development of cerebral infarction has focused attention on the potential of antiinflammatory treatment strategies for stroke. Interferon (IFN)- Methods--After 60 minutes of middle cerebral artery occlusion, rats (n=12/group) were treated with IV tail injections of 8 or 16 µg of IFN- Results--IFN- Conclusions--Our results suggest that additional preclinical studies are warranted.
Revised on December 13, 2005
Accepted on January 20, 2006
Interferon-
Carolina M. Maier PhD; 
Fails to Protect in a Model of Transient Focal Stroke
, an immunomodulatory agent approved for treatment of multiple sclerosis, is being evaluated in a phase I clinical trial in acute ischemic stroke. In the present study, we evaluated the effects of wild-type rat IFN- and its pegylated counterpart (PEG-IFN-) in a model of focal ischemia and reperfusion. in 300 µL of PBS once daily for 3 or 7 days or with IV or SC injections of PEG-IFN- for 1 day. The animals were assessed daily for weight and for neurological findings. Additional animals underwent complete hematology and chemistry profiles, as well as complete multiorgan necropsy studies. All of the brain tissue was evaluated for assessment of infarct areas, neutrophil infiltration, and presence of hemorrhagic transformations. and PEG-IFN- failed to protect against experimental ischemic brain injury as assessed by histopathology and neurological outcome. Furthermore, IFN- treatment was associated with significant weight loss and alterations in hematology and chemistry profiles.
Key words: inflammation • interferon
•
ischemia •
neuroprotection
This article has been cited by other articles:
 |
|
 |
|
  B. Marsh, S. L. Stevens, A. E. B. Packard, B. Gopalan, B. Hunter, P. Y. Leung, C. A. Harrington, and M. P. Stenzel-Poore Systemic Lipopolysaccharide Protects the Brain from Ischemic Injury by Reprogramming the Response of the Brain to Stroke: A Critical Role for IRF3 J. Neurosci., August 5, 2009; 29(31): 9839 - 9849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Philip, M. Benatar, M. Fisher, and S. I. Savitz Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials Stroke, February 1, 2009; 40(2): 577 - 581. [Abstract] [Full Text] [PDF]
|
|